Project Grant HT94252310239
Award Date
9/1/23
Completion Date
8/31/26
Dollars Obligated
$819K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $931,113 project grant to The University of Texas MD Anderson Cancer Center, with a performance period from November 1, 2024 to October 31, 2027. The grant supports research targeting RNA surveillance machinery in neurofibromatosis type 1 (NF1)-mutant malignant peripheral nerve sheath tumors (MPNSTs). As a leading academic cancer research institution, MD Anderson has extensive expertise...
The University of Texas MD Anderson Cancer Center received a $1,041,605 Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) to conduct research titled "INTERROGATING TUMOR-IMMUNE-NEURON CROSS TALK AT SINGLE-CELL RESOLUTION IN A PANEL OF NOVEL SOMATIC TRANSGENIC NF1 TUMOR MODELS". This 3-year award, starting on September 1, 2023, will support basic and translational cancer research focused on understanding the interactions...
This $1,619,723 federal Project Grant award from the Department of Defense's Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides funding to The University of Texas MD Anderson Cancer Center to conduct research targeting novel mediators of breast cancer brain metastasis. The award period runs from April 1, 2024 to March 31, 2027, with the goal of developing new treatments, improving patient care, and advancing scientific understanding in this...
This $3,945,543 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports cancer research and care initiatives at the University of Texas MD Anderson Cancer Center (MD Anderson). The award will fund a 4-year clinical research extension project to advance progress, precision, and equity in breast cancer care. MD Anderson, a leading comprehensive cancer center, will utilize the funding to conduct research activities that...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,619,668 project grant to The University of Texas MD Anderson Cancer Center to inhibit brain metastases of HER2/neu-positive breast cancers using extracellular vesicles from renovated dendritic cells. The award began on May 1, 2024 and is scheduled for completion on April 30, 2027. The project aims to develop innovative treatments to improve outcomes for military service members and the...
The University of Texas MD Anderson Cancer Center received a $567,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on September 1, 2024, will fund research targeting myeloid mimicry in renal medullary carcinoma, with a completion date of August 31, 2027. Through this federal grant, MD Anderson Cancer Center will conduct innovative scientific studies, ranging from basic laboratory research to advanced...
The University of Texas MD Anderson Cancer Center received a $647,990 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). This three-year grant, effective June 1, 2024, supports research to investigate cell plasticity and epigenetic reprogramming mechanisms underlying the transition of well-differentiated to de-differentiated liposarcoma. The funding will enable basic research, translational studies, and potentially future...
The U.S. Defense Health Agency has awarded a $7,001,734 Project Grant to The University of Texas MD Anderson Cancer Center to advance the understanding of metastatic breast cancer through the development of a comprehensive research platform. The grant, which runs from August 15, 2024 to August 14, 2028, is funded under the Military Medical Research and Development (CFDA 12.420) program. The project aims to drive innovative cancer research and explore new approaches to prevention, diagnosis,...
The University of Texas MD Anderson Cancer Center received a $647,998 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award will fund research to develop image-guided, bidirectional EphB4 agonist-based therapy for ovarian cancer over a 4-year period from September 1, 2023 to August 31, 2027. MD Anderson, a comprehensive cancer treatment and research center, has extensive experience conducting basic,...
The University of Texas MD Anderson Cancer Center was awarded a $1,295,977 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund a measurement burst study from September 2021 through September 2025 to examine short- and long-term change and variability in adjustment trajectories among young adult cancer patient-caregiver dyads. Through the support of basic, applied, and advanced...